Wu, Wei
Zhang, Yu http://orcid.org/0000-0003-4087-6544
Jiang, Jing
Lucas, Molly V.
Fonzo, Gregory A.
Rolle, Camarin E.
Cooper, Crystal
Chin-Fatt, Cherise
Krepel, Noralie
Cornelssen, Carena A.
Wright, Rachael http://orcid.org/0000-0002-8242-9796
Toll, Russell T.
Trivedi, Hersh M. http://orcid.org/0000-0002-2583-2300
Monuszko, Karen
Caudle, Trevor L.
Sarhadi, Kamron
Jha, Manish K.
Trombello, Joseph M. http://orcid.org/0000-0002-4953-3831
Deckersbach, Thilo
Adams, Phil
McGrath, Patrick J.
Weissman, Myrna M.
Fava, Maurizio
Pizzagalli, Diego A. http://orcid.org/0000-0002-7772-1143
Arns, Martijn http://orcid.org/0000-0002-0610-7613
Trivedi, Madhukar H. http://orcid.org/0000-0002-2983-1110
Etkin, Amit http://orcid.org/0000-0001-8259-3521
Funding for this research was provided by:
National Natural Science Foundation of China (61876063, 61836003)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (DP1MH116506, U01MH092221, U01MH092250, U01MH092221, R01MH103324, R01MH103324, U01MH092250, U01MH092250, U01MH092221, U01MH092221, U01MH092221, U01MH092250, U01MH092250, U01MH092221, U01MH092221, U01MH092250, U01MH092250, U01MH092221, U01MH092221, U01MH092250, U01MH092250, U01MH092221, U01MH092221, U01MH092250, U01MH092250, R01MH103324, DP1MH116506)
Stanford Neurosciences Institute
Article History
Received: 8 December 2018
Revised: 6 December 2019
Accepted: 17 December 2019
First Online: 10 February 2020
Competing interests
: A.E. (lifetime disclosure) has been receiving salary and equity from Alto Neuroscience since 1 November 2019, to which the pending patent for SELSER has been licensed from Stanford. He holds equity in Mindstrong Health, Akili Interactive and Sizung for unrelated work, has received research funding from the National Institute of Mental Health, Department of Veterans Affairs, Cohen Veterans Bioscience, Brain and Behavior Research Foundation, Dana Foundation, Brain Resource Inc. and the Stanford Neurosciences Institute and consulted for Cervel, Takaeda, Posit Science, Acadia, Otsuka, Lundbeck and Janssen. Over the past 3 years, D.A.P. has received consulting fees from Alkermes, BlackThorn Therapeutics, Boehreinger Ingelheim, Posit Science and Takeda Pharmaceuticals. He has received funding from NIMH, the Dana Foundation and Brain and Behavior Research Foundation. T.D.’s research has been funded by NIH, NIMH, National Alliance for Research on Schizophrenia & Depression, TSA, IOCDF, Tufts University, DBDAT and Otsuka Pharmaceuticals. He has received honoraria, consultation fees and/or royalties from the MGH Psychiatry Academy, BrainCells Inc., Clintara, LLC, Inc., Systems Research and Applications Corporation, Boston University, the Catalan Agency for Health Technology Assessment and Research, the National Association of Social Workers Massachusetts, the Massachusetts Medical Society, Tufts University, National Institute of Drug Abuse, NIMH, Oxford University Press, Guilford Press and Rutledge. He has also participated in research funded by DARPA, NIH, NIA, Agency for Healthcare Research and Quality, PCORI, Janssen Pharmaceuticals, The Forest Research Institute, Shire Development Inc., Medtronic, Cyberonics, Northstar and Takeda. P.M. has received funding from the National Institute of Mental Health, New York State Department of Mental Hygiene, Research Foundation for Mental Hygiene (New York State), Forest Research Laboratories, Sunovion Pharmaceuticals and Naurex Pharmaceuticals (now Allergan). In the past 2 years, M.W. received funding from the NIMH, the National Institute on Drug Abuse, the National Alliance for Research on Schizophrenia and Depression, the Sackler Foundation, the Templeton Foundation; and receives royalties from the Oxford University Press, Perseus Press, the American Psychiatric Association Press and MultiHealth Systems. M.F. has received research support from Abbot Laboratories; Alkermes, Inc.; American Cyanamid; Aspect Medical Systems; AstraZeneca; Avanir Pharmaceuticals; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon; Clintara, LLC; Cerecor; Covance; Covidien; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; Ganeden Biotech, Inc.; GlaxoSmithKline; Harvard Clinical Research Institute; Hoffman-LaRoche; Icon Clinical Research; i3 Innovus/Ingenix; Janssen R&D, LLC; Jed Foundation; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante; Methylation Sciences Inc.; National Alliance for Research on Schizophrenia & Depression; National Center for Complementary and Alternative Medicine; National Institute of Drug Abuse; NIMH; Neuralstem, Inc.; Novartis AG; Organon Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; Pharmacia-Upjohn; Pharmaceutical Research Associates., Inc.; Pharmavite LLC; PharmoRx Therapeutics; Photothera; Reckitt Benckiser; Roche Pharmaceuticals; RCT Logic, LLC (formerly Clinical Trials Solutions, LLC); Sanofi-Aventis US LLC; Shire; Solvay Pharmaceuticals, Inc.; Stanley Medical Research Institute; Synthelabo; Tal Medical; and Wyeth-Ayerst Laboratories. He has served as advisor or consultant to Abbott Laboratories; Acadia; Affectis Pharmaceuticals AG; Alkermes, Inc.; Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Avanir Pharmaceuticals; AXSOME Therapeutics; Bayer AG; Best Practice Project Management, Inc.; Biogen; BioMarin Pharmaceuticals, Inc.; Biovail Corporation; BrainCells Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Cerecor; CNS Response, Inc.; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dinippon Sumitomo Pharma Co. Inc.; Dov Pharmaceuticals, Inc.; Edgemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; ePharmaSolutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; Forum Pharmaceuticals; GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH; i3 Innovus/Ingenis; Intracellular; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante, Inc.; Merck & Co., Inc.; MSI Methylation Sciences, Inc.; Naurex, Inc.; Nestle Health Sciences; Neuralstem, Inc.; Neuronetics, Inc.; NextWave Pharmaceuticals; Novartis AG; Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Osmotica; Otsuka Pharmaceuticals; Pamlab, LLC.; Pfizer Inc.; PharmaStar; Pharmavite LLC.; PharmoRx Therapeutics; Precision Human Biolaboratory; Prexa Pharmaceuticals, Inc.; Puretech Ventures; PsychoGenics; Psylin Neurosciences, Inc.; RCT Logic, LLC Formerly Clinical Trials Solutions, LLC; Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; Sanofi-Aventis US LLC.; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; Supernus Pharmaceuticals, Inc.; Synthelabo; Taisho Pharmaceutical; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; Tetragenex Pharmaceuticals, Inc.; TransForm Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Vanda Pharmaceuticals, Inc.; and VistaGen. He has received speaking or publishing fees from Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc.; CME Institute/Physicians Postgraduate Press, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy/Primedia; MGH Psychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource, Corp.; and Wyeth-Ayerst Laboratories. He has equity holdings in Compellis and PsyBrain, Inc.; he has a patent for Sequential Parallel Comparison Design, which is licensed by MGH to Pharmaceutical Product Development, LLC (PPD); and a patent application for a combination of Ketamine plus Scopolamine in Major Depressive Disorder, licensed by MGH to Biohaven; and he receives copyright royalties for the MGH Cognitive & Physical Functioning Questionnaire, Sexual Functioning Inventory, ATRQ, Discontinuation-Emergent Signs & Symptoms, Symptoms of Depression Questionnaire, and SAFER; Lippincott, Williams & Wilkins; Wolkers Kluwer; and World Scientific Publishing Co. Pte. Ltd. M.H.T. is or has been an advisor/consultant and received fees from (lifetime disclosure): Abbott Laboratories, Inc., Abdi Ibrahim, Akzo (Organon Pharmaceuticals Inc.), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb Company, Cephalon, Inc., Cerecor, CME Institute of Physicians, Concert Pharmaceuticals, Inc., Eli Lilly & Company, Evotec, Fabre-Kramer Pharmaceuticals, Inc., Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, LLC, Janssen Pharmaceutica Products, LP, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Inc., Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals, Inc., Pfizer Inc., PgxHealth, Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products Ltd., Sepracor, SHIRE Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus and Wyeth-Ayerst Laboratories. In addition, he has received grants/research support from: Agency for Healthcare Research and Quality, Cyberonics, Inc., National Alliance for Research in Schizophrenia and Depression, National Institute of Mental Health and the National Institute on Drug Abuse. J.M.T. currently owns stock in Merck and Gilead Sciences and within the past 36 months has previously owned stock in Johnson & Johnson. M.A. holds options from Brain Resource, is Director and Owner of Research Institute Brainclinics, has equity in neuroCare Group and is co-inventor on four patent applications (A61B5/0402; US2007/0299323, A1; WO2010/139361 A1) related to EEG, neuromodulation and psychophysiology, but does not own these nor receives any proceeds related to these patents; he receives Research Institute Brainclinics funding from Brain Resource and neuroCare Group and equipment support from Deymed, neuroConn and Magventure. All other authors report no competing interests.